This Avicenna Alliance working group aims to deploy in silico methods downstream and design comprehensive solutions (process, access to research, software, hardware, humanware, possibly services) to allow any organization to time and cost effectively adopt and deploy in silico methods all along the development, registration and life cycle of the products.
Are you a VPHi member? Join this new Avicenna Alliance working group led by by Cecile Rousseau, PhD (VCLS) and Emmanuelle Voisin, PhD (VCLS).
Digital evidence can and must be used for regulatory approval in all parts of the world. The Research & Technology Working Group has made huge progress, which now allows to start applying modeling and simulation, as properly defined, to accelerate medical innovation access to patients.
Many organizations are willing to invest in in silico but practical implementation guidance is needed:
The key goals of this group are:
Deploy in silico methods to optimize and streamline product quality and manufacturing through the product life-cycle.
Regulatory: Identify and address the challenge to deploy Computer Modelling and Simulation & Artificial Intelligence to refine, reduce or replace animal studies and clinical trials.
Promote and implement in silico medicine in healthcare, including clinical diagnostics (e.g., clinical decision support tool and AI-powered pathology), “proactive” vigilance.
Priorities 2023 - 2024 and beyond:
2025 and beyond:
If you're interested to join please contact email@example.com
Get an overview of the working groups and related task forces, by downloading this brochure